MaxCyte - delivering growth, highlighting value
MaxCyte (LON:MXCT) delivered a consensus-beating 30% step up in 2019 (FY19) revenues, driven by sales of licences for its proprietary cell engineering platform and early clinical milestones from some of its eight clinical/commercial licences, reaching a five-year revenue compound annualised growth rate (CAGR) of 25%. With more than US$650mln in potential pre-commercial milestones payable from its eight clinical/commercial licences with cell therapy partners, recent advances in its partners’ development programmes are set to translate into further upside to core revenues from FY20. With its novel cell therapy platform CARMA now separated into a wholly-owned subsidiary, targeting self-sufficiency by 2021, and key data due from its lead asset mid-2020, there is increasing visibility on the value and prospects of both its technology and therapeutic divisions.
Quick facts: MaxCyte Inc
Price: 206 GBX
Market Cap: £157.77 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE